Claims
- 1. A compound selected from those of formula (I): ##STR14## in which: R.sub.1 represents hydrogen or lower alkyl,
- n represents 1 or 2,
- A represents oxygen or sulfur,
- X represents a CH.sub.2 group,
- R.sub.2 represents hydrogen or lower alkyl or lower acyl and R.sub.3 represents (CH.sub.2)pR.sub.4, with p being an integer from 1 and 6, inclusive, and R.sub.4 represents:
- a nitrile group, in which case R.sub.3 represents (CH.sub.2).sub.p-1 R.sub.4, or halogen or amino optionally substituted with:
- (lower alkyl) sulfonyl,
- phenylsulfonyl optionally substituted on the phenyl ring with one or more lower alkyl, lower alkoxy, hydroxyl, or trifluoromethyl groups or a halogen atom,
- one or two (C.sub.1 -C.sub.6) acyl groups optionally substituted with a lower alkyl, lower alkoxy, or hydroxyl group, a halogen atom, or a phenyl, thienyl, benzothienyl, indolyl, furyl, or benzofuryl group, the phenyl, thienyl, benzo-thienyl, indolyl, furyl and benzofuryl groups themselves optionally being substituted with one or more lower alkyl, lower alkoxy, or hydroxyl groups or a halogen atom,
- one or two linear or branched (C.sub.1 -C.sub.6) alkyl groups,
- or R.sub.4 represents any one of the following groups: ##STR15## in which: Y and Y', which may be identical or different, represent hydrogen, halogen or lower alkyl, lower alkoxy, or hydroxyl group,
- m is 1 or 2,
- its enantiomers, diastereoisomers, and epimers, and its addition salts with a pharmaceutically-acceptable acid or a pharmaceutically-acceptable base when R.sub.1 =H.
- 2. A compound selected from those of claim 1 for which R.sub.1 represents a CH.sub.3 group, its enantiomers, epimers and diastereoisomers and its addition salts with a pharmaceutically-acceptable acid or a pharmaceutically-acceptable base when R.sub.1 =H.
- 3. A compound selected from those of claim 1 for which A represents a sulfur atom, its enantiomers, epimers and diastereoisomers as well as its addition salts with a pharmaceutically-acceptable acid or a pharmaceutically-acceptable base when R.sub.1 =H.
- 4. A compound selected from those of claim 1 for which A represents an oxygen atom and X represents a CH.sub.2 group, its enantiomers, epimers and diastereoisomers as well as its addition salts with a pharmaceutically-acceptable acid or a pharmaceutically-acceptable base when R.sub.1 =H.
- 5. A compound selected from those of claim 1 for which the group (CH.sub.2 --CH.sub.2).sub.n --NR.sub.2 R.sub.3 is at position b, its enantiomers, epimers and diastereoisomers as well as its addition salts with a pharmaceutically-acceptable acid or a pharmaceutically-acceptable base when R.sub.1 =H.
- 6. A compound selected from those of claim 1 for which the group (CH.sub.2 --CH.sub.2).sub.n --NR.sub.2 R.sub.3 is at position c, its enantiomers, epimers and diastereoisomers as well as its addition salts with a pharmaceutically-acceptable acid or a pharmaceutically-acceptable base when R.sub.1 =H.
- 7. A compound selected from those of claim 1 for which the group (CH.sub.2 --CH.sub.2).sub.n --NR.sub.2 R.sub.3 is at position d, its enantiomers, epimers and diastereoisomers as well as its addition salts with a pharmaceutically-acceptable acid or a pharmaceutically-acceptable base when R.sub.1 =H.
- 8. A compound selected from those of claim 1 for which X represents a CH.sub.2 group, A represents a sulfur atom, n is equal to 1, and R.sub.3 represents a group (CH.sub.2)pR.sub.4, with p being 1 to 6, inclusive, and R.sub.4 represents:
- an amino group substituted with a phenylsulfonyl group optionally substituted on the phenyl ring with one or more lower alkyl, lower alkoxy, hydroxyl, or trifluoromethyl groups or a halogen atom,
- or alternatively any one of the following groups: ##STR16## in which: Y and Y', which may be identical or different, represent hydrogen, halogen lower alkyl, lower alkoxy, or hydroxyl,
- m is 1 or 2,
- its enantiomers, epimers and diastereoisomers and its addition salts with a pharmaceutically-acceptable acid or a pharmaceutically-acceptable base when R.sub.1 =H.
- 9. A compound as claimed in claim 1 which is selected from 3-[4-{N-[2-(4-methyl-2,3-dihydro-3-oxo-1,4-benzoxazin-7-yl)ethyl]amino}butyl]-2,4-dioxo-3-azaspiro[4.5]decane, and its addition salts with a pharmaceutically-acceptable acid.
- 10. A compound as claimed in claim 1 which is selected from 4-methyl-7-[2-{N-[4-(4,4-dimethyl-2,6-dioxo-1-piperidyl)butyl]amino}ethyl]-2,3-dihydro-3-oxobenzoxazine, and its addition salts with a pharmaceutically-acceptable acid.
- 11. A compound of claim 1 which is 4-methyl-7-{2-[N-(3-phthalimidopropyl)-N-n-propylamino]ethyl}-3-oxo-2,3-dihydro-1,4-benzoxazine of the formula ##STR17##
- 12. A compound of claim 1 which is 3-[4-{N-[2-(4-methyl-3-oxo-2,3-dihydro-1,4-benzoxazin-7-yl)ethyl]amino}butyl]-2,4-dioxo-3-azabicyclo[3.3.0]octane of the formula ##STR18##
- 13. A compound of claim 1 which is 4-methyl-7-{4-[N-(2-phthalimidoethyl)amino]butyl}-2,3-dihydro-3-oxo-1,4-benzoxazine of the formula ##STR19##
- 14. A compound of claim 1 which is 4-methyl-7-[4-{N-methyl-N-[2-(para-tolylsulfonylamino)ethyl]amino}butyl]-2,3-dihydro-3-oxo1,4-benzoxazine of the formula ##STR20##
- 15. A pharmaceutical composition containing as active principle an effective antidepressive or anxiolytic amount of a 5-HT.sub.1A agonist, being at least one compound as claimed in claim 1, in combination with one or more pharmaceutically-acceptable excipients or vehicles.
- 16. A method for treating a mammal afflicted with a condition requiring for its treatment an antidepressive or anxiolytic amount of a 5-HT.sub.1A receptor agonist comprising the step of administering to the said mammal an amount of a compound of claim 1 which is effective for alleviation of said conditions.
Priority Claims (1)
Number |
Date |
Country |
Kind |
90 11866 |
Sep 1990 |
FRX |
|
Parent Case Info
This application is a division of our prior-filed copending U.S. application Ser. No. 07/945,492, filed Sep. 16, 1992, now allowed, which in turn is a division of Ser. No. 07/765,959, filed Sep. 26, 1991, now U.S. Pat. No. 5,196,434.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
3770734 |
Pesson et al. |
Nov 1973 |
|
5225409 |
Taverne et al. |
Jul 1993 |
|
Foreign Referenced Citations (6)
Number |
Date |
Country |
0110781 |
Jun 1984 |
EPX |
0171702 |
Feb 1986 |
EPX |
0174811 |
Mar 1986 |
EPX |
0223674 |
May 1987 |
EPX |
0281309 |
Sep 1988 |
EPX |
2035749 |
Dec 1970 |
FRX |
Non-Patent Literature Citations (5)
Entry |
Life Sciences 49, p. 37; "Use of a Conflict Procedure in Pigeons to Characterize Anxiolytic Drug Activity: Evaluation of Activity", etc. (1991), Koek et al. |
"The Pharmacological Basis of Therapeutics" by Goodman and Gilman, Eighth Edition (1990) p. 429. |
J. Med. Chem. 30, 1166.sub.]1176 (1987), Weinstock et al. |
Acta Ther. 13(2), 125-129 (1987), Brunet et al. |
Il Farmaco 44(1), 77-88 (1989), Moussavi et al. |
Divisions (2)
|
Number |
Date |
Country |
Parent |
945492 |
Sep 1992 |
|
Parent |
765959 |
Sep 1991 |
|